cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Surface Oncology Inc
12 own
12 watching
Current Price
$0.97
$0
(0.15%)
logo-surf
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
58.82M
52-Week High
52-Week High
3.81
52-Week Low
52-Week Low
0.6024
Average Volume
Average Volume
0.16M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
26.344
iconMarket Capitalization58.82M
icon52-Week High3.81
icon52-Week Low0.6024
iconAverage Volume0.16M
iconDividend Yield--
iconP/E Ratio26.344
What does the Surface Oncology Inc do?
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Surface Oncology Inc make?
News & Events about Surface Oncology Inc.
Globe Newswire
24days ago
Surface Oncology initiates clinical trial with antibody discovered using Vaccinexs ActivMAb Antibody Discovery PlatformROCHESTER, N.Y., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and ...
Globe Newswire
28days ago
SRF114 is designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment and has demonstrated highly specific CCR8-exclusive binding and reduced tumor growth in pre-clinical studies Initial clinical data anticipated in 2024 CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- ...
Globe Newswire
2 months ago
Data further support SRF388 and SRF114 clinical development programsCAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the ...
PR Newswire
7 months ago
Thinking about buying stock in Inspira Technologies, Annovis Bio, Tenneco, Benitec Biopharma, or Surface Oncology? Thinking about buying stock in Inspira Technologies, Annovis Bio, Tenneco, Benitec Biopharma, or Surface Oncology? PR Newswire NEW YORK, July 7, 2022 NEW YORK, July 7, 2022...
Globe Newswire
7 months ago
- Non-clinical findings further support the potential of SRF388 to treat patients suffering from liver cancer - CAMBRIDGE, Mass., June 20, 2022 (GLOBE NEWSWIRE) -- Surface Oncology(Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the ...
Frequently Asked Questions
Frequently Asked Questions
What is Surface Oncology Inc share price today?
plus_minus_icon
Can Indians buy Surface Oncology Inc shares?
plus_minus_icon
How can I buy Surface Oncology Inc shares from India?
plus_minus_icon
Can Fractional shares of Surface Oncology Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Surface Oncology Inc stocks?
plus_minus_icon
What is today’s traded volume of Surface Oncology Inc?
plus_minus_icon
What is today’s market capitalisation of Surface Oncology Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Surface Oncology Inc?
plus_minus_icon
What percentage is Surface Oncology Inc down from its 52-Week High?
plus_minus_icon
What percentage is Surface Oncology Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.97
$0
(0.15%)
logo-surf
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00